Drugs / BAY1830839
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05003089 | Jun → Dec 2021 | immune dysregulation, autoimmunity, and autoinflammation | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03965728 | Jun 2019 → Jan 2022 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03540615 | Jun 2018 → Feb 2019 | rheumatoid arthritis | Bayer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY1830839 | “BAY1830839” NCT03965728 ↗ |
| Route | Oral | “single oral doses of BAY1830839” NCT03540615 ↗ |